comprehensive -WSS

comprehensive

author：hotspot 2025-10-01 18:23:18 - browse：63881

Adobe

WASHINGTON — The federal government increasingly is scrutinizing Chinese businesses and their interactions with American companies, including in the biotech sector. Chinese biotechnology companies, the thinking goes, could threaten national security by giving the Chinese government access to the genetic and health information of Americans.

Just Wednesday, President Biden issued an executive order aimed at keeping sensitive data, including Americans’ genetic information, out of the hands of adversaries.

But American biotech companies worry they could become collateral damage if the government sloppily targets sanctions. They’re pushing back against legislation that would bar biotech companies from working with some Chinese companies, especially as the government takes aim at WuXi, a Chinese company considered a crucial partner for discovering, testing, and making medicines that has worked with such brands as Pfizer, AstraZeneca, and GSK.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Readout Newsletter: New research from Sanofi, Regeneron, etc.

knowledge

WSS

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Testing for cancer recurrence creates a new limbo for patients

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Chimpanzees, like humans and whales, get menopause: Study

Readout Newsletter: XBI biotech index, Akero Therapeutics

Diversifying clinical trials isn't enough to close racial gaps: study

focus

comprehensive

entertainment

Wildfire smoke exposes gaps in outdoor worker protections

Novo: Oral version of Ozempic leads to 15% weight loss

Drug repurposing or repositioning? The language matters

Biden's order seeks to regulate AI risk without stifling innovation

Trump demands the U.S. pay no more for drugs than other countries … again

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

As demand for Covid shots wanes, Moderna seeks its next success

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Trump demands the U.S. pay no more for drugs than other countries … again

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

focus

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Readout Newsletter: What happened with Sarepta's Duchenne data

A public health expert passes on football's full body collisions for youths

Living organ donors deserve priority status for transplants

The pink breast cancer awareness ribbon needs a redesign

FDA approves first new drug developed for postpartum depression

hotspot

knowledge

focus

hotspot